UNSPSC 51433920: Manidipine

This classification denotes a calcium channel blocker with the molecular formula C35H38N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6O4754US88, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl ester but generally known as manidipine, which bears US NIH Compound Identifier 4008. European Medicines Agency schedules Manidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08641MIG.

UNSPSC 51433920 Manidipine, a Commodity code, encompasses emergency and hospital medications that state and local governments procure through public health departments, fire rescue operations, and health and human services agencies. While the code nominally describes a specific antihypertensive agent, recent state and local solicitations under this code show active procurement of generic multi-source pharmaceuticals, over-the-counter products, and advanced life support medications—items purchased in volume by emergency medical services, hospital systems, and state pharmacy benefit programs. Issuing bodies include municipal purchasing departments (city fire rescue), state health and human services commissions, and multistate cooperative purchasing alliances. The work involves supplying pharmaceuticals through authorized wholesale channels, meeting FDA compliance and Good Manufacturing Practices certification, maintaining inventory with specified shelf-life requirements, and fulfilling rapid-delivery obligations to public-sector health and emergency-response operations.

Geographic activity spans Florida, Texas, and Minnesota, with Minnesota's multistate cooperative purchasing vehicle (MMCAP) aggregating demand across multiple state and local participants including Oregon. Recent representative opportunities include the City of Tampa's sealed-bid procurement (26P00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount; the Texas Health and Human Services Commission's Request for Information (HHS0017013) posted April 3, 2026, to assess vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels; and MMCAP's Request for Proposal (S1070000015802) posted January 20, 2026, with a March 26, 2026 response deadline, requiring vendors to supply generic pharmaceuticals and OTC products through three authorized wholesalers with pricing effective July 1, 2026. All solicitations require comprehensive compliance documentation, including Safety Data Sheets, cGMP certification, and Drug Supply Chain Security Act adherence, with performance penalties for reporting or onboarding failures.